Browsing Tag
Medicare
26 posts
BrightSpring Health Services reports $101m quarterly profit as healthcare expansion accelerates
BrightSpring raises 2026 guidance as revenue climbs 26% to $4.21 billion and adjusted EBITDA surges 42%. Explore the growth outlook.
How did an OpenAI AI agent gain unauthorized access to an Australian government site?
Australia is investigating how an OpenAI agent gained unauthorized access to public and non-public files on a government Medicare statistics portal after encountering access restrictions during a research task. Officials say there is currently no evidence that personal patient records were accessed, while OpenAI says its models took actions the company did not intend.
OpenAI agent breaches Australian Medicare portal as government launches AI security investigation
An OpenAI agent breached Australia’s Medicare statistics portal without being told to hack it. Find out why the incident is alarming AI experts.
Tempus AI agrees to acquire Personalis in $1.5bn precision oncology deal built around a $46 floor price
Tempus AI to buy Personalis at $16.25 per share in a $1.5B stock-plus-optional-cash deal, with a $46 Tempus floor that gives Personalis the right to walk if breached.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Why California’s healthcare fraud crackdown could become a major political test
Find out how California’s healthcare fraud crackdown could reshape taxpayer oversight, Medicaid scrutiny and political accountability today!
Lumos Diagnostics Holdings Limited puts FebriDx US rollout at centre of ASX:LDX rerating test
Find out how Lumos Diagnostics Holdings is using FebriDx US adoption to test whether ASX:LDX can turn regulatory wins into revenue.
How opioid reduction strategies are driving cost savings in orthopedic surgery pathways
Find out how Pacira BioSciences, Inc. is using EXPAREL data to drive opioid reduction and cost savings in Medicare orthopedic surgery pathways.
FDA approves Lilly’s Foundayo as second oral GLP-1 weight loss pill, challenging Novo Nordisk’s head start
FDA approves Eli Lilly's Foundayo (orforglipron), the second oral GLP-1 obesity pill with no food restrictions. What this means for LLY investors and patients. Read more.
How FDA-aligned endpoints position inFoods IBS alongside drug therapies
Biomerica, Inc. aligns inFoods IBS with FDA drug endpoints and secures Medicare pricing. See what this means for IBS competitors and investors.